NDA 200656 · Fresenius Kabi USA
Kabiven In Plastic Container
Amino Acids, Calcium Chloride, Dextrose, Magnesium Sulfate, Potassium Chloride, Sodium Acetate, Sodium Glycerophosphate, Soybean Oil · Intravenous · Lipid Emulsion; Amino Acid
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 25, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30,323
6,603 Phase 3, 2,682 recruiting
FAERS reports
399
394 serious, 75 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 15, 2025.
PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. ( 1 ) Limitations of Use: Not recommended for use in pediatric patients <2 years including preterm infants because the fixed content of the formulation does not meet nutritional requirements in this age group. ( 1 , 5.1 , 8.4 ) Limitations of Use: PERIKABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] .
Mechanism: PERIKABIVEN is used as a supplement or as the sole source of nutrition in patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy. The administered dextrose is oxidized to carbon dioxide and water, yielding energy. Intravenously administered lipids provide a biologically utilizable source of calories and essential fatty acids. Fatty acids serve...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
7 products under this application
- KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (2053ML) · EMULSION, INTRAVENOUS · Prescription
- KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML ; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (1026ML) · EMULSION, INTRAVENOUS · Prescription
- PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (1920ML) · EMULSION, INTRAVENOUS · Prescription
- KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (2566ML) · EMULSION, INTRAVENOUS · Prescription
- KABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 3.3%; CALCIUM CHLORIDE 29MG/100ML; DEXTROSE 9.8GM/100ML; MAGNESIUM SULFATE 96MG/100ML; POTASSIUM CHLORIDE 174MG/100ML; SODIUM ACETATE 239MG/100ML; SODIUM GLYCEROPHOSPHATE 147MG/100ML; SOYBEAN OIL 3.9GM/100ML (1540ML) · EMULSION, INTRAVENOUS · Prescription
- PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML ; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (2400ML) · EMULSION, INTRAVENOUS · Prescription
- PERIKABIVEN IN PLASTIC CONTAINER · AMINO ACIDS 2.4%; CALCIUM CHLORIDE 20MG/100ML; DEXTROSE 6.8GM/100ML; MAGNESIUM SULFATE 68MG/100ML; POTASSIUM CHLORIDE 124MG/100ML; SODIUM ACETATE 170MG/100ML; SODIUM GLYCEROPHOSPHATE 105MG/100ML; SOYBEAN OIL 3.5GM/100ML (1440ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT07790523 · 410,000 participants (planned) · Start Sep 1, 2026 · Primary completion May 31, 2028
Drug: mCombriax® (mRNA-1083); Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) · For: COVID-19; Influenza
Sites: Hellerup, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- Community Level Interventions for Pre-eclampsiaPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01911494 · 87,500 participants (planned) · Start Sep 2013 · Primary completion May 2018
Drug: Magnesium Sulfate; Methyldopa · For: Pre-eclampsia; Hypertension, Pregnancy Induced
Sites: Belagavi, India; Maputo, Mozambique; Sagamu, Nigeria · 4 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsPivotal-lookingCompleted
BioNTech SEIndustry
NCT04368728 · 46,969 participants · Start Apr 29, 2020 · Primary completion Feb 10, 2023
Drug: BNT162b1; BNT162b2 and 1 more · For: SARS-CoV-2 Infection; COVID-19
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 175 sites in all
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19Pivotal-lookingCompleted
Tor Biering-SørensenAcademic, hospital or other
NCT07279766 · 41,060 participants · Start Dec 11, 2025 · Primary completion Aug 26, 2026
Drug: mRNA-1273 (Moderna COVID-19 vaccine) · For: COVID-19
Sites: Hellerup, Denmark; Søborg, Denmark
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT04470427 · 30,415 participants · Start Jul 27, 2020 · Primary completion Dec 29, 2022
Drug: mRNA-1273; Placebo · For: SARS-CoV-2
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chills30
- pyrexia24
- nausea22
- chest discomfort21
- palpitations20
- vomiting20
- death19
- pneumonia19
- asthenia18
- diarrhoea18
- dyspnoea18
- foetal growth restriction17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 6 |
| 2010 | 7 |
| 2011 | 9 |
| 2012 | 35 |
| 2013 | 12 |
| 2014 | 10 |
| 2015 | 11 |
| 2016 | 23 |
| 2017 | 24 |
| 2018 | 15 |
| 2019 | 9 |
| 2020 | 11 |
| 2021 | 14 |
| 2022 | 16 |
| 2023 | 79 |
| 2024 | 57 |
| 2025 | 28 |
| 2026 | 13 |
Recalls
1 FDA enforcement reports for this application.
Apr 28, 2015 · Class II · Terminated
Labeling: Label Error on Declared Strength: Labeled 3.1% Amino Acids but contains 3.3% Amino Acids
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis.
Saunders B, Elliott-Sale K, Artioli GG, et al. · Br J Sports Med 2017 · Meta-Analysis, Systematic Review
- Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.
Gielen E, Beckwée D, Delaere A, et al. · Nutr Rev 2021 · Meta-Analysis, Systematic Review
- Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis.
Picca A, Coelho-Junior HJ, Calvani R, et al. · Ageing Res Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Chan V, Lo K · Postgrad Med J 2022 · Meta-Analysis, Systematic Review
- Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.
Guasch-Ferré M, Hruby A, Toledo E, et al. · Diabetes Care 2016 · Meta-Analysis, Systematic Review
- The Effect of Amino Acids on Wound Healing: A Systematic Review and Meta-Analysis on Arginine and Glutamine.
Arribas-López E, Zand N, Ojo O, et al. · Nutrients 2021 · Meta-Analysis, Systematic Review
Sponsor: Fresenius Kabi USA · Also marketed as Perikabiven In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.